Search Results - Kamil Paruch
- Showing 1 - 5 results of 5
-
1
-
2
BRCA1 or CDK12 loss sensitizes cells to CHK1 inhibitors by Hana Paculová, Juraj Kramara, Šárka Šimečková, Radek Fedr, Karel Souček, Ondřej Hylse, Kamil Paruch, Marek Svoboda, Martin Mistrík, Jiří Kohoutek
Published in Tumor Biology (2017-10-01)Get full text
Article -
3
The CHK1 inhibitor MU380 significantly increases the sensitivity of human docetaxel‐resistant prostate cancer cells to gemcitabine through the induction of mitotic catastrophe by Stanislav Drápela, Prashant Khirsariya, Wytske M. vanWeerden, Radek Fedr, Tereza Suchánková, Diana Búzová, Jan Červený, Aleš Hampl, Martin Puhr, William R. Watson, Zoran Culig, Lumír Krejčí, Kamil Paruch, Karel Souček
Published in Molecular Oncology (2020-10-01)Get full text
Article -
4
Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells by Miroslav Boudny, Jana Zemanova, Prashant Khirsariya, Marek Borsky, Jan Verner, Jana Cerna, Alexandra Oltova, Vaclav Seda, Marek Mraz, Josef Jaros, Zuzana Jaskova, Michaela Spunarova, Yvona Brychtova, Karel Soucek, Stanislav Drapela, Marie Kasparkova, Jiri Mayer, Kamil Paruch, Martin Trbusek
Published in Haematologica (2019-12-01)Get full text
Article -
5
Characterization of an RNA binding protein interactome reveals a context-specific post-transcriptional landscape of MYC-amplified medulloblastoma by Michelle M. Kameda-Smith, Helen Zhu, En-Ching Luo, Yujin Suk, Agata Xella, Brian Yee, Chirayu Chokshi, Sansi Xing, Frederick Tan, Raymond G. Fox, Ashley A. Adile, David Bakhshinyan, Kevin Brown, William D. Gwynne, Minomi Subapanditha, Petar Miletic, Daniel Picard, Ian Burns, Jason Moffat, Kamil Paruch, Adam Fleming, Kristin Hope, John P. Provias, Marc Remke, Yu Lu, Tannishtha Reya, Chitra Venugopal, Jüri Reimand, Robert J. Wechsler-Reya, Gene W. Yeo, Sheila K. Singh
Published in Nature Communications (2022-12-01)Get full text
Article
